ZELTIA SA Net revenues totalled 84.4 million euro (+7.8%).
Yondelis® net sales increased by 11.4% to 43.6 million euro. Group EBITDA amounted to 9.5 million euro, following a 28% increase in R&D expenditure, which reflects clinical progress of the product pipeline.
Madrid, 28 July 2015: Zeltia (Grupo Zeltia, ZEL.MC) announces its financial and corporate results for the first half of 2015. Zeltia Group reported total net revenues of 84.4 million euro in the first half of 2015, a 7.8% increase compared with the same period of 2014. The biopharmaceutical area reported revenues of 46.6 million euro (+11.8%), with Yondelis® accounting for 43.6 million euro in sales, an 11.4% increase with respect to the first half of 2014. Part of that growth was due to the sale of raw materials for 3.3 million euro, mainly to Janssen Products LP.
The consumer chemicals division reported 37 million euro in net sales, up from 36 million euro in the same period of 2014.
The Zeltia group obtained 9.5 million euro in EBITDA in the first six months of
2015, compared with 22 million euro in the same period of 2014. There are two main factors of that difference in the EBITDA between the two periods. On one hand, R&D expenditure increased in the first half of 2015 as a result of progress of the oncology pipeline. The company recently announced the completion of enrolment for the Phase III trial with Aplidin to treat multiple myeloma. The further two Phase III trials with PM1183 are expected to be under way before the year- end. The first trial, which commenced recently, is for the treatment of platinum- resistant ovarian
cancer patients, and the second will be initiated in the indication of small-cell lung cancer (SCLC). R&D expenditure in the first half of 2015 amounted to 30.5 million euro (vs. 23.8 million euro in the same period of 2014).
Additionally, other operating revenues amounted to 11.7 million euro in the first half of 2015, compared with 19.8 million euro in the same period last year. This year, PharmaMar collected a 10 million dollar milestone payment under the agreement signed with Janssen Products LP in 2011. Under the same agreement, in
2014 PharmaMar received the milestone payment of 25 million dollars. In case
commercialisation of Yondelis® for the treatment of soft tissue sarcoma is approved in the US and Japan, the company expects to obtain other milestone payments this year under the current licensing agreements with Janssen Products LP and our Japanese partner, Taiho Pharmaceuticals. The Yondelis® PDUFA date is October 24
2015 for potential approval in the US by the FDA.
Overall, the group reported 3.33 million euro in net attributable profit during the first half of 2015 (vs. 17.7 million euro in the first half of 2014).
Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine- based drugs for use in oncology. The Zeltia group consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.
For more information +34 91 444 4500This note is also available on the Zeltia web site: www.zeltia.com
|
distributed by
|
